201 related articles for article (PubMed ID: 38489051)
1. The efficacy of zuranolone versus placebo in postpartum depression and major depressive disorder: a systematic review and meta-analysis.
Winslow M; White E; Rose SJ; Salzer E; Nemec EC
Int J Clin Pharm; 2024 Jun; 46(3):590-601. PubMed ID: 38489051
[TBL] [Abstract][Full Text] [Related]
2. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.
Walkery A; Leader LD; Cooke E; VandenBerg A
Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of some new GABAkines for treatment of depression: A systematic review and meta-analysis from randomized controlled trials.
Zou J; Yang L; Yang G; Gao J
Psychiatry Res; 2023 Oct; 328():115450. PubMed ID: 37683318
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of zuranolone for the treatment of depression: A systematic review and meta-analysis.
Li Z; Wu Q; Peng P; Wu M; Liu S; Liu T
Psychiatry Res; 2024 Jan; 331():115640. PubMed ID: 38029628
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of Zuranolone for treatment of depression: A systematic review and meta-analysis.
Fayoud AM; Orebi HA; Elshnoudy IA; Elsebaie MAT; Elewid MMM; Sabra HK
Psychopharmacology (Berl); 2024 Jul; 241(7):1299-1317. PubMed ID: 38802705
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis.
Cha DS; Kleine N; Teopiz KM; Di Vincenzo JD; Ho R; Galibert SL; Samra A; Zilm SPM; Cha RH; d'Andrea G; Gill H; Ceban F; Meshkat S; Wong S; Le GH; Kwan ATH; Rosenblat JD; Rhee TG; Mansur RB; McIntyre RS
Expert Opin Pharmacother; 2024; 25(1):5-14. PubMed ID: 38164653
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Zuranolone: The First FDA-Approved Oral Treatment Option for Postpartum Depression.
Barnes KN; Vogl CM; Nelson LA
Ann Pharmacother; 2024 Jul; 58(7):728-734. PubMed ID: 37876133
[TBL] [Abstract][Full Text] [Related]
9. Zuranolone: A Narrative Review of a New Oral Treatment for Postpartum Depression.
Hitt EM
Clin Ther; 2024 May; 46(5):433-438. PubMed ID: 38697873
[TBL] [Abstract][Full Text] [Related]
10. The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials.
Clayton AH; Suthoff E; Jain R; Kosinski M; Fridman M; Deligiannidis KM; Meltzer-Brody S; Chen SY; Gervitz L; Huang MY; Trivedi M; Bonthapally V
J Affect Disord; 2024 Apr; 351():904-914. PubMed ID: 38325605
[TBL] [Abstract][Full Text] [Related]
11. Zuranolone for treatment of major depressive disorder: a systematic review and meta-analysis.
Ahmad A; Awan AR; Nadeem N; Javed AS; Farooqi M; Daniyal M; Mumtaz H
Front Neurosci; 2024; 18():1361692. PubMed ID: 38726035
[TBL] [Abstract][Full Text] [Related]
12. Zuranolone, a neuroactive drug, used in the treatment of postpartum depression by modulation of GABA
Sharma R; Bansal P; Saini L; Sharma N; Dhingra R
Pharmacol Biochem Behav; 2024 May; 238():173734. PubMed ID: 38387651
[TBL] [Abstract][Full Text] [Related]
13. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial.
Deligiannidis KM; Meltzer-Brody S; Gunduz-Bruce H; Doherty J; Jonas J; Li S; Sankoh AJ; Silber C; Campbell AD; Werneburg B; Kanes SJ; Lasser R
JAMA Psychiatry; 2021 Sep; 78(9):951-959. PubMed ID: 34190962
[TBL] [Abstract][Full Text] [Related]
14. Different dosage regimens of zuranolone in the treatment of major depressive disorder: A meta-analysis of randomized controlled trials.
Lian J; Lin Z; Li X; Chen G; Wu D
J Affect Disord; 2024 Jun; 354():206-215. PubMed ID: 38479510
[TBL] [Abstract][Full Text] [Related]
15. Exploring the clinical potentials of zuranolone in managing postpartum depression: A new therapeutic horizon.
Nashwan AJ; Rehan ST; Imran L; Abbas SG; Khan SF
Prog Neuropsychopharmacol Biol Psychiatry; 2024 Jun; 132():110983. PubMed ID: 38412941
[TBL] [Abstract][Full Text] [Related]
16. Using Matching-Adjusted Indirect Comparisons and Network Meta-analyses to Compare Efficacy of Brexanolone Injection with Selective Serotonin Reuptake Inhibitors for Treating Postpartum Depression.
Cooper MC; Kilvert HS; Hodgkins P; Roskell NS; Eldar-Lissai A
CNS Drugs; 2019 Oct; 33(10):1039-1052. PubMed ID: 31642037
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of zuranolone versus selective serotonin reuptake inhibitors for the treatment of postpartum depression in the United States.
O'Callaghan L; Chertavian E; Johnson SJ; Ferries E; Deligiannidis KM
J Med Econ; 2024; 27(1):492-505. PubMed ID: 38465615
[TBL] [Abstract][Full Text] [Related]
18. Indirect comparisons of relative efficacy estimates of zuranolone and selective serotonin reuptake inhibitors for postpartum depression.
Meltzer-Brody S; Gerbasi ME; Mak C; Toubouti Y; Smith S; Roskell N; Tan R; Chen SS; Deligiannidis KM
J Med Econ; 2024; 27(1):582-595. PubMed ID: 38523596
[TBL] [Abstract][Full Text] [Related]
19. Brexanolone for postpartum depression.
Hutcherson TC; Cieri-Hutcherson NE; Gosciak MF
Am J Health Syst Pharm; 2020 Feb; 77(5):336-345. PubMed ID: 32073124
[TBL] [Abstract][Full Text] [Related]
20. Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression.
Deligiannidis KM; Citrome L; Huang MY; Acaster S; Fridman M; Bonthapally V; Lasser R; Kanes SJ
J Clin Psychiatry; 2023 Jan; 84(1):. PubMed ID: 36724109
[No Abstract] [Full Text] [Related]
[Next] [New Search]
